PHRRF PHARMATHER HOLDINGS LTD
- 0.166100
- -0.011800-6.63%
PHARMATHER HOLDINGS LTD News
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
PharmaTher Expects FDA to Decide on Ketamine Approval by April 29
PharmaTher Provides Update for Expected FDA Approval of Ketamine
TORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB:PHRRF) (CSE:PHRM), a specialty pharmaceutical company, is pleased to provide an update for the Company's lead
Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More
Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of psychedeli
PharmaTher Is 'One Step Closer To Being A Ketamine Leader' Due To FDA Acceptance
The Food and Durg Administration (FDA) has accepted specialty biopharma company PharmaTher Holdings' (OTCQB:PHRRF) new drug application for a racemic ketamine product. What Happened: The so-called go
PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX (Ketamine)
FDA assigns GDUFA goal date of April 29, 2024 Milestone builds upon PharmaTher's commitment toward unlocking the potential of ketamine for unmet medical needs TORONTO, Sept. 27, 2023 (GLOBE NEWSWIRE) -- PharmaTher
With Ecstasy a Potential PTSD Therapy, Psychedelic Treatments Could Take off
NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035.
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK's Struggle For Reclassification Nonprofit medical research organization the Usona Institute sha
PharmaTher Aims To Mitigate Ketamine Shortage With New FDA Application
Specialty biotech company PharmaTher Holdings (OTCQB:PHRRF) reported it has submitted a priority-original Abbreviated New Drug Application (ANDA) for its proprietary racemic ketamine, KETARX, to the F
PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX (Ketamine) to the FDA
TORONTO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB:PHRRF) (CSE:PHRM), a commercial-focused specialty pharmaceutical company, is pleased to announce it has
Psyched: Germany Ships LSD Prodrugs Via DHL, Minneapolis Decriminalizes, Wiz Khalifa's Magic Pitch & More
Minneapolis Mayor Deprioritizes Psychedelics: 'We Should Be In The Business Of Helping People' Minneapolis Mayor Jacob Frey recently signed an executive order effectively deprioritizing criminal prose
PharmaTher's DMT Patch Shows Positive Outcomes, Investment Toward The Clinical Stage
PharmaTher Holdings and the Terasaki Institute for Biomedical Innovation evaluated the former's novel microneedle patch for the delivery of DMT, and research yielded positive outcomes.
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
World's Largest Psychedelics Conference Boasts 12K Attendees The Multidisciplinary Association for Psychedelic Studies (MAPS) sponsored a Psychedelic Science conference in Denver last week, which gath
BetterLife Fast Tracks Its US Patent For Non-Hallucinogenic Compound And Other LSD Derivatives
Psychedelics biotech BetterLife Pharma Inc. (OTCQB:BETRF) is fast-tracking its U.S. patent application covering the composition of matter, treatment uses and a novel production method of non-hallucino
Ketamine News: PharmaTher Begins FDA Filing For KETARX Application, Stella Acquires Field Trip Assets
Specialty biotech company PharmaTher Holdings Ltd. (OTCQB:PHRRF) has filed a pre-submission facility correspondence in advance of its Abbreviated New Drug Application (ANDA) for its novel racemic keta
PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX (Racemic Ketamine) to the FDA
TORONTO, June 27, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB:PHRRF) (CSE:PHRM), a commercial-focused specialty pharmaceutical company, is pleased to announce it has filed a
PharmaTher's Novel Ketamine Heads For The US Market With New Collaboration Agreement
Psychedelics biotech PharmaTher Holdings (OTCQB:PHRRF) has entered into a collaborative partnership with pharma marketing company Vitruvias Therapeutics for the commercialization of its proprietary ra
PharmaTher and Vitruvias Enter Into Collaboration Agreement for Commercialization of KETARX (Racemic Ketamine) in the U.S.
TORONTO, June 20, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB:PHRRF) (CSE:PHRM), a commercial-focused specialty pharmaceutical company, is pleased to announce it has entered
Parkinson's Patients May Benefit From Ketamine, PharmaTher Applies For FDA Fast Track
Specialty pharmaceutical company PharmaTher Holdings (OTCQB:PHRRF) has submitted a Fast Track Application to the Food and Drug Administration (FDA) for KETARX, a ketamine drug that may help treat levo
Analysis
Price Target
No Data
